Marshall Wace, LLP Syndax Pharmaceuticals Inc Transaction History

Marshall Wace, LLP

$63.3 Billion
Q1 2024

A detailed history of Marshall Wace, LLP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 2,032,059 shares of SNDX stock, worth $41.7 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

2,032,059

Previous 2,101,911 3.32%

Holding current value

$41.7 Million

Previous $45.4 Million 6.47%

% of portfolio

0.08%

Previous 0.08%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $1.38 Million - $1.72 Million	-69,852 Reduced 3.32%	2,032,059 $48.4 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $17.1 Million - $32.5 Million	1,497,949 Added 248.02%	2,101,911 $45.4 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $8.77 Million - $13.1 Million	603,962 New	603,962 $8.77 Million
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $1.34 Million - $1.91 Million	-97,981 Reduced 89.38%	11,637 $224,000
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $1.45 Million - $2.17 Million	97,981 Added 841.98%	109,618 $1.91 Million

Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $161,405 - $230,412	11,637 New	11,637 $222,000
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $3.7 Million - $4.72 Million	-191,788 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $2.9 Million - $5.07 Million	191,788 New	191,788 $4.27 Million
Q2 2020 Aug 13, 2020	SELL	$8.94 - $20.98 $476,189 - $1.12 Million	-53,265 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$6.65 - $12.03 $354,212 - $640,777	53,265 New	53,265 $584,000

Others Institutions Holding SNDX

# of Institutions

195

Shares Held

90M

Call Options Held

353K

Put Options Held

207K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1.16B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Syndax Pharmaceuticals Inc Transaction History